Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.

Schauer SP, Mylott WR Jr, Yuan M, Jenkins RG, Rodney Mathews W, Honigberg LA, Wildsmith KR.

Alzheimers Res Ther. 2018 Nov 28;10(1):118. doi: 10.1186/s13195-018-0445-0.

2.

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R.

Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5.

3.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

4.

Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.

Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A, van Lookeren Campagne M, Le KN, Graham RR, Beres T, Bhangale TR, Honigberg LA, Smith A, Henry EC, Ho C, Strauss EC; MAHALO Study Investigators.

Sci Transl Med. 2017 Jun 21;9(395). pii: eaaf1443. doi: 10.1126/scitranslmed.aaf1443.

PMID:
28637922
5.

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.

Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ; Alzheimer's Disease Neuroimaging Initiative; Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team.

Proteomics Clin Appl. 2015 Aug;9(7-8):715-31. doi: 10.1002/prca.201400178. Epub 2015 Apr 24.

6.

Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.

Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, Kaur S, Mathews WR, Honigberg LA.

Mol Neurodegener. 2014 Jun 6;9:22. doi: 10.1186/1750-1326-9-22.

7.

Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

MacGlashan D Jr, Honigberg LA, Smith A, Buggy J, Schroeder JT.

Int Immunopharmacol. 2011 Apr;11(4):475-9. doi: 10.1016/j.intimp.2010.12.018. Epub 2011 Jan 14.

8.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.

9.

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.

MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW.

Leukemia. 2008 Jul;22(7):1354-60. doi: 10.1038/leu.2008.126. Epub 2008 Jun 12.

PMID:
18548107
10.

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT.

ChemMedChem. 2007 Jan;2(1):58-61. No abstract available.

PMID:
17154430
11.

Identification of substrates of human protein-tyrosine phosphatase PTPN22.

Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, Tang J, Jeffery D, Mortara K, Sampang J, Williams SR, Buggy J, Clark JM.

J Biol Chem. 2006 Apr 21;281(16):11002-10. Epub 2006 Feb 6.

12.

A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.

Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK.

Am J Hum Genet. 2004 Aug;75(2):330-7. Epub 2004 Jun 18.

Supplemental Content

Loading ...
Support Center